Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.3%

2 terminated/withdrawn out of 15 trials

Success Rate

84.6%

-1.9% vs industry average

Late-Stage Pipeline

40%

6 trials in Phase 3/4

Results Transparency

27%

3 of 11 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 3

5(38.5%)

Phase 2

4(30.8%)

Phase 1

3(23.1%)

Phase 4

1(7.7%)

13Total

Phase 3(5)

Phase 2(4)

Phase 1(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT06915233Phase 3Recruiting

A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle

Role: lead

NCT03588975Phase 3Recruiting

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Role: lead

NCT00765518Phase 2Completed

Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

Role: lead

NCT01483898Phase 3Completed

An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

Role: lead

NCT01020968Phase 2Completed

Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

Role: lead

NCT01670981Phase 2Completed

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

Role: lead

NCT00719576Phase 3Completed

Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee

Role: lead

NCT01251588Completed

Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee

Role: lead

NCT00140634Completed

The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients

Role: lead

NCT00797550Phase 1Terminated

Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion

Role: lead

NCT00158613Phase 4Completed

Study of the Treatment of Articular Repair (STAR)

Role: lead

NCT00424567Phase 1Terminated

Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.

Role: lead

NCT00468000Phase 2Completed

Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

Role: lead

NCT00505219Phase 3Completed

Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head

Role: lead

NCT00755911Phase 1Completed

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

Role: collaborator

All 15 trials loaded